Events & Promotions
|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
May 0510:00 AM PDT
-11:00 AM PDT
GMAT Inequalities is a high-frequency topic in GMAT Quant, but many students struggle because the concepts behave differently from standard algebra. Understanding the right rules, patterns, and edge cases can significantly improve both speed and accuracy.- May 06
08:30 AM PDT
-09:30 AM PDT
In Episode 3 of our GMAT Ninja Critical Reasoning series, we tackle Discrepancy, Paradox, and Explain an Oddity questions. You know the feeling: the passage gives you two facts that seem completely contradictory.... - May 08
08:00 AM PDT
-08:30 AM PDT
Join the special YouTube live-stream for selecting the winners of GMAT Club MBA Scholarships sponsored by Juno live. Watch who gets these coveted MBA scholarships offered by GMAT Club and Juno.
21 Aug 2025, 21:04
Kudos
Bookmarks
The system used by American venture capitalists is often lauded for its dynamism, high risk tolerance, and capacity for swift scaling. Yet a body of longitudinal research suggests that the same model often encourages short-term exits, limiting the scope for sustainable growth. Indeed, data indicate that U.S. venture funding has soared in recent years, reflecting an unprecedented appetite for brisk expansions. This market-driven allocation mechanism—where venture firms channel funds into emerging businesses—sometimes prioritizes rapid valuations over long-term viability. However, no consensus exists on whether patient capital always outperforms aggressive scaling. In contrast, some analyses show that countries such as Finland rely more heavily on public-private partnerships that foster strategic mentorship and steady capital infusions, allowing entrepreneurs to refine their products and cultivate enduring customer bases. American investors, holding diversified stakes in many early-stage companies, often lack the bandwidth for deep, ongoing evaluations. As a result, they rely on immediate metrics such as monthly user growth, overshadowing broader indicators like robust team development or resilient supply chains. Consequently, valuations can fluctuate wildly in response to brief changes in consumer demand, fueling risky behavior and misallocation of capital toward trendy sectors while leaving potentially transformative, slower-growing fields underfunded.
This short-term focus also influences how founders allocate their internal resources. Managers often justify outlays through traditional financial models grounded in near-term performance, reminiscent of the “by-the-numbers” approach described in widely cited management studies. When quick profitability becomes paramount, expenditures on human capital—such as employee training or team-building programs—are viewed as costs rather than investments. Start-ups commonly pare back mentorship initiatives and long-term research projects to preserve immediate cash flow, aiming to satisfy venture boards and protect valuations. In countries emphasizing patient capital, by contrast, firms enjoy greater freedom to cultivate intangible assets that underpin lasting growth. According to a recent study, ventures receiving patient financing were likelier to pursue research projects. While the American venture-capital system undoubtedly propels many enterprises to rapid prominence, its short horizon can sow precarious conditions for both investors and companies. True competitiveness arises when businesses balance swift expansion with ongoing capability enhancement, ensuring that innovation endures beyond fleeting market cycles. This approach not only fosters long-term stability but also safeguards stakeholders’ interests by promoting consistent innovation, strategic resource utilization, and a more resilient entrepreneurial ecosystem overall.
Given the author’s views, what is the most likely near- and long-term effect on a VC-backed U.S. start-up’s valuation if it decides to expand its research division?
A. Its valuation would decline under short-term metrics and would necessarily rebound once the research concludes.
B. Investor attention would shift to non-quantifiable assets, causing a permanent decrease in market value regardless of research outcomes.
C. Higher research costs would push most current investors to divest, and the valuation would rarely recover, even if the project eventually produces salable innovations.
D. It could incur an initial valuation dip yet recover only if the research demonstrably enhances future revenue.
E. Its valuation would rise immediately, as investors prize cutting-edge research for its potential to yield high returns in the short run.
This short-term focus also influences how founders allocate their internal resources. Managers often justify outlays through traditional financial models grounded in near-term performance, reminiscent of the “by-the-numbers” approach described in widely cited management studies. When quick profitability becomes paramount, expenditures on human capital—such as employee training or team-building programs—are viewed as costs rather than investments. Start-ups commonly pare back mentorship initiatives and long-term research projects to preserve immediate cash flow, aiming to satisfy venture boards and protect valuations. In countries emphasizing patient capital, by contrast, firms enjoy greater freedom to cultivate intangible assets that underpin lasting growth. According to a recent study, ventures receiving patient financing were likelier to pursue research projects. While the American venture-capital system undoubtedly propels many enterprises to rapid prominence, its short horizon can sow precarious conditions for both investors and companies. True competitiveness arises when businesses balance swift expansion with ongoing capability enhancement, ensuring that innovation endures beyond fleeting market cycles. This approach not only fosters long-term stability but also safeguards stakeholders’ interests by promoting consistent innovation, strategic resource utilization, and a more resilient entrepreneurial ecosystem overall.
Given the author’s views, what is the most likely near- and long-term effect on a VC-backed U.S. start-up’s valuation if it decides to expand its research division?
A. Its valuation would decline under short-term metrics and would necessarily rebound once the research concludes.
B. Investor attention would shift to non-quantifiable assets, causing a permanent decrease in market value regardless of research outcomes.
C. Higher research costs would push most current investors to divest, and the valuation would rarely recover, even if the project eventually produces salable innovations.
D. It could incur an initial valuation dip yet recover only if the research demonstrably enhances future revenue.
E. Its valuation would rise immediately, as investors prize cutting-edge research for its potential to yield high returns in the short run.
21 Aug 2025, 21:04
Kudos
Bookmarks
Official Solution:
The system used by American venture capitalists is often lauded for its dynamism, high risk tolerance, and capacity for swift scaling. Yet a body of longitudinal research suggests that the same model often encourages short-term exits, limiting the scope for sustainable growth. Indeed, data indicate that U.S. venture funding has soared in recent years, reflecting an unprecedented appetite for brisk expansions. This market-driven allocation mechanism—where venture firms channel funds into emerging businesses—sometimes prioritizes rapid valuations over long-term viability. However, no consensus exists on whether patient capital always outperforms aggressive scaling. In contrast, some analyses show that countries such as Finland rely more heavily on public-private partnerships that foster strategic mentorship and steady capital infusions, allowing entrepreneurs to refine their products and cultivate enduring customer bases. American investors, holding diversified stakes in many early-stage companies, often lack the bandwidth for deep, ongoing evaluations. As a result, they rely on immediate metrics such as monthly user growth, overshadowing broader indicators like robust team development or resilient supply chains. Consequently, valuations can fluctuate wildly in response to brief changes in consumer demand, fueling risky behavior and misallocation of capital toward trendy sectors while leaving potentially transformative, slower-growing fields underfunded.
This short-term focus also influences how founders allocate their internal resources. Managers often justify outlays through traditional financial models grounded in near-term performance, reminiscent of the “by-the-numbers” approach described in widely cited management studies. When quick profitability becomes paramount, expenditures on human capital—such as employee training or team-building programs—are viewed as costs rather than investments. Start-ups commonly pare back mentorship initiatives and long-term research projects to preserve immediate cash flow, aiming to satisfy venture boards and protect valuations. In countries emphasizing patient capital, by contrast, firms enjoy greater freedom to cultivate intangible assets that underpin lasting growth. According to a recent study, ventures receiving patient financing were likelier to pursue research projects. While the American venture-capital system undoubtedly propels many enterprises to rapid prominence, its short horizon can sow precarious conditions for both investors and companies. True competitiveness arises when businesses balance swift expansion with ongoing capability enhancement, ensuring that innovation endures beyond fleeting market cycles. This approach not only fosters long-term stability but also safeguards stakeholders’ interests by promoting consistent innovation, strategic resource utilization, and a more resilient entrepreneurial ecosystem overall.
Given the author’s views, what is the most likely near- and long-term effect on a VC-backed U.S. start-up’s valuation if it decides to expand its research division?
A. Its valuation would decline under short-term metrics and would necessarily rebound once the research concludes.
B. Investor attention would shift to non-quantifiable assets, causing a permanent decrease in market value regardless of research outcomes.
C. Higher research costs would push most current investors to divest, and the valuation would rarely recover, even if the project eventually produces salable innovations.
D. It could incur an initial valuation dip yet recover only if the research demonstrably enhances future revenue.
E. Its valuation would rise immediately, as investors prize cutting-edge research for its potential to yield high returns in the short run.
A) Incorrect. Guarantees a rebound as soon as the research ends; the passage allows only a possible long-term benefit, contingent on whether the R&D ultimately proves its commercial worth.
B) Incorrect. Predicts a permanent valuation drop regardless of outcomes, an extreme claim the author never makes. The passage stresses uncertainty, not irreparable damage.
C) Incorrect. States that higher research costs would drive most investors away and that recovery would be “rarely” achievable, quite a bit overstating the author’s point. The passage mentions an initial dip, not a mass exodus or near-certain failure.
D) Correct Answer. Matches up with the author’s balanced view: under short-term metrics the startup may suffer an immediate valuation hit, but recovery is conditional on demonstrable revenue gains from the research, exactly what the passage suggests.
E) Incorrect. Claims the valuation would spike right away because investors prize cutting-edge research; the passage states that most VC investors focus on near-term profits, so they would not boost valuation simply because the firm expands its research division.
Answer: D
The system used by American venture capitalists is often lauded for its dynamism, high risk tolerance, and capacity for swift scaling. Yet a body of longitudinal research suggests that the same model often encourages short-term exits, limiting the scope for sustainable growth. Indeed, data indicate that U.S. venture funding has soared in recent years, reflecting an unprecedented appetite for brisk expansions. This market-driven allocation mechanism—where venture firms channel funds into emerging businesses—sometimes prioritizes rapid valuations over long-term viability. However, no consensus exists on whether patient capital always outperforms aggressive scaling. In contrast, some analyses show that countries such as Finland rely more heavily on public-private partnerships that foster strategic mentorship and steady capital infusions, allowing entrepreneurs to refine their products and cultivate enduring customer bases. American investors, holding diversified stakes in many early-stage companies, often lack the bandwidth for deep, ongoing evaluations. As a result, they rely on immediate metrics such as monthly user growth, overshadowing broader indicators like robust team development or resilient supply chains. Consequently, valuations can fluctuate wildly in response to brief changes in consumer demand, fueling risky behavior and misallocation of capital toward trendy sectors while leaving potentially transformative, slower-growing fields underfunded.
This short-term focus also influences how founders allocate their internal resources. Managers often justify outlays through traditional financial models grounded in near-term performance, reminiscent of the “by-the-numbers” approach described in widely cited management studies. When quick profitability becomes paramount, expenditures on human capital—such as employee training or team-building programs—are viewed as costs rather than investments. Start-ups commonly pare back mentorship initiatives and long-term research projects to preserve immediate cash flow, aiming to satisfy venture boards and protect valuations. In countries emphasizing patient capital, by contrast, firms enjoy greater freedom to cultivate intangible assets that underpin lasting growth. According to a recent study, ventures receiving patient financing were likelier to pursue research projects. While the American venture-capital system undoubtedly propels many enterprises to rapid prominence, its short horizon can sow precarious conditions for both investors and companies. True competitiveness arises when businesses balance swift expansion with ongoing capability enhancement, ensuring that innovation endures beyond fleeting market cycles. This approach not only fosters long-term stability but also safeguards stakeholders’ interests by promoting consistent innovation, strategic resource utilization, and a more resilient entrepreneurial ecosystem overall.
Given the author’s views, what is the most likely near- and long-term effect on a VC-backed U.S. start-up’s valuation if it decides to expand its research division?
A. Its valuation would decline under short-term metrics and would necessarily rebound once the research concludes.
B. Investor attention would shift to non-quantifiable assets, causing a permanent decrease in market value regardless of research outcomes.
C. Higher research costs would push most current investors to divest, and the valuation would rarely recover, even if the project eventually produces salable innovations.
D. It could incur an initial valuation dip yet recover only if the research demonstrably enhances future revenue.
E. Its valuation would rise immediately, as investors prize cutting-edge research for its potential to yield high returns in the short run.
A) Incorrect. Guarantees a rebound as soon as the research ends; the passage allows only a possible long-term benefit, contingent on whether the R&D ultimately proves its commercial worth.
B) Incorrect. Predicts a permanent valuation drop regardless of outcomes, an extreme claim the author never makes. The passage stresses uncertainty, not irreparable damage.
C) Incorrect. States that higher research costs would drive most investors away and that recovery would be “rarely” achievable, quite a bit overstating the author’s point. The passage mentions an initial dip, not a mass exodus or near-certain failure.
D) Correct Answer. Matches up with the author’s balanced view: under short-term metrics the startup may suffer an immediate valuation hit, but recovery is conditional on demonstrable revenue gains from the research, exactly what the passage suggests.
E) Incorrect. Claims the valuation would spike right away because investors prize cutting-edge research; the passage states that most VC investors focus on near-term profits, so they would not boost valuation simply because the firm expands its research division.
Answer: D
03 Sep 2025, 21:01
Kudos
Bookmarks
I don’t quite agree with the solution. The entire passage is highlighting the advantages of long-term investing cycle over a short one.
The question is asking about the typical U.S. Venture-Capitalist's behaviour.
Given in the passage, the typical VC in U.S. would do the following - "the same model often encourages short-term exits".
It's in the investor's interest to inflate the price for a short-term exit. Which is what E says.
The question is asking about the typical U.S. Venture-Capitalist's behaviour.
Given in the passage, the typical VC in U.S. would do the following - "the same model often encourages short-term exits".
It's in the investor's interest to inflate the price for a short-term exit. Which is what E says.
